The GPCRs will be used as antigens for the discovery and development of antibodies. Credit: National Cancer Institute on Unsplash.

Confo Therapeutics and AbCellera have entered a research partnership to discover GPCR [specific G protein-coupled receptor ligand]-targeting antibody candidates.

The collaboration will use Confo Therapeutics’ suite of ConfoBody-enabled antibody discovery technologies on two undisclosed GPCR targets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ConfoBody technology will help to stabilise the selected GPCRs in their disease-relevant conformations.

These GPCRs will be leveraged as antigens for the discovery and development of antibodies.

Confo Therapeutics will be eligible to receive upfront payments, milestones and tiered royalties on the net sales of the product.

Confo Therapeutics CEO Cedric Ververken stated: “We are thrilled to start this collaboration with AbCellera to discover the best possible antibody candidates against two challenging GPCR targets.

“This serves as an additional validation, recognising the power of Confo’s platform and our ability to overcome the limitations of GPCR antibody discovery.

“Entering into select, high-value collaborations allows us to efficiently deploy our platform together with leading companies while we continue to build out our own pipeline of innovative and impactful medicines.”

Combined with pharmacologic and biologic insight, Confo Therapeutics’ platform allows the company to develop a multi-indication drug candidates pipeline with the aim of transforming therapeutic outcomes for patients living with severe illnesses.

In March 2023, Confo Therapeutics and Eli Lilly and Company entered a global licence agreement for the former’s clinical-stage peripheral pain candidate, CFTX-1554.

Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.